US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
DE60131430T2
(de)
|
2000-01-14 |
2008-10-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
ATE384072T1
(de)
*
|
2000-09-26 |
2008-02-15 |
Idera Pharmaceuticals Inc |
Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
|
ES2347525T3
(es)
*
|
2000-12-27 |
2010-11-02 |
Dynavax Technologies Corporation |
Polinucleotidos inmunomoduladores y metodos para usuarios.
|
GB0114719D0
(en)
*
|
2001-06-15 |
2001-08-08 |
Glaxo Group Ltd |
Compound
|
EP2423335B1
(de)
|
2001-06-21 |
2014-05-14 |
Dynavax Technologies Corporation |
Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
AU2002361468A1
(en)
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
US7276489B2
(en)
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
EP1393745A1
(de)
*
|
2002-07-29 |
2004-03-03 |
Hybridon, Inc. |
Modulierung der immunstimulierenden Eigenschaften von Oligonukleotiden und Analoga durch optimale Darstellung der 5'-Enden
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
US8263091B2
(en)
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
PT2353608T
(pt)
|
2002-10-11 |
2020-03-11 |
Novartis Vaccines And Diagnostics S R L |
Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
|
JP2006512927A
(ja)
|
2002-12-11 |
2006-04-20 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
5’cpg核酸およびその使用方法
|
KR101309501B1
(ko)
|
2002-12-23 |
2013-09-24 |
다이나박스 테크놀로지 코퍼레이션 |
면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
MXPA05007652A
(es)
*
|
2003-01-16 |
2006-02-22 |
Hybridon Inc |
Modulacion de propiedades inmunoestimulantes de compuestos basados en oligonucleotido mediante la utilizacion de dinucleotidos inmunoestimulantes modificados.
|
DK1587537T3
(da)
|
2003-01-30 |
2012-07-16 |
Novartis Ag |
Injicerbare vacciner mod multiple meningococ-serogrupper
|
US7354907B2
(en)
*
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
ES2385933T3
(es)
|
2003-02-20 |
2012-08-03 |
University Of Connecticut Health Center |
Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina.
|
KR100681470B1
(ko)
|
2003-03-03 |
2007-02-12 |
연세대학교 산학협력단 |
면역반응 증진용 올리고뉴크레오타이드
|
US20060257852A1
(en)
|
2003-04-10 |
2006-11-16 |
Chiron Corporation |
Severe acute respiratory syndrome coronavirus
|
US7569554B2
(en)
|
2003-05-16 |
2009-08-04 |
Idera Pharmaceuticals, Inc. |
Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
|
AU2004252505B2
(en)
*
|
2003-06-11 |
2010-10-28 |
Idera Pharmaceuticals, Inc. |
Stabilized immunomodulatory oligonucleotides
|
EP2363141A1
(de)
|
2003-07-15 |
2011-09-07 |
Idera Pharmaceuticals, Inc. |
Zusammensetzung zwei Oligonukleotide und IL-2 enthaltend, wobei die Oligonukleotide direkt über ihre 3' Enden mitander verknüpft sind und eines der beiden ein frei zugängliches 5' Ende hat, welche zur Auslösung einer Immunantwort in einem Patienten verwendet wird.
|
JP4989225B2
(ja)
*
|
2003-09-25 |
2012-08-01 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
核酸親油性接合体
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
SI1961426T1
(sl)
|
2003-10-02 |
2011-10-28 |
Novartis Ag |
Kombinirana cepiva proti meningitisu
|
BRPI0416079A
(pt)
|
2003-10-30 |
2007-01-02 |
Coley Pharm Gmbh |
análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
|
KR101138131B1
(ko)
|
2003-12-08 |
2012-04-23 |
이데라 파마슈티칼즈, 인코포레이티드 |
작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절
|
JP4817599B2
(ja)
*
|
2003-12-25 |
2011-11-16 |
独立行政法人科学技術振興機構 |
免疫活性増強剤とこれを用いた免疫活性の増強方法
|
CA2555105A1
(en)
*
|
2004-02-20 |
2005-09-09 |
Hybridon, Inc. |
Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
|
WO2005107797A1
(en)
|
2004-03-09 |
2005-11-17 |
Chiron Corporation |
Influenza virus vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
MXPA06011994A
(es)
|
2004-04-30 |
2007-01-25 |
Chiron Srl |
Vacunacion con conjugado de meningococos.
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2811027A1
(de)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus-Vektoren für RSV- und PIV-Impfstoffe
|
WO2006080946A2
(en)
*
|
2004-06-08 |
2006-08-03 |
Coley Pharmaceutical Gmbh |
Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
|
EP2901856B1
(de)
*
|
2004-06-15 |
2017-08-09 |
Idera Pharmaceuticals, Inc. |
Immunstimulatorische Oligonukleotidmultimere
|
US7427405B2
(en)
*
|
2004-06-15 |
2008-09-23 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory oligonucleotide multimers
|
US20060165716A1
(en)
|
2004-07-29 |
2006-07-27 |
Telford John L |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
MY159370A
(en)
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
DE102004051804A1
(de)
*
|
2004-10-21 |
2006-04-27 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
WO2006089264A2
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
CN101180312A
(zh)
|
2005-02-18 |
2008-05-14 |
诺华疫苗和诊断公司 |
来自尿路病原性大肠杆菌的免疫原
|
EP2329843A3
(de)
|
2005-04-18 |
2011-09-14 |
Novartis Vaccines and Diagnostics, Inc. |
Expression des Hepatitis-B-Virus-Oberflächenantigens zur Impfstoffherstellung
|
US20100017895A1
(en)
|
2005-07-18 |
2010-01-21 |
Amy Weiner |
Small animal model for hcv replication
|
US20110223197A1
(en)
|
2005-10-18 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and Systemic Immunization with Alphavirus Replicon Particles
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
NZ567978A
(en)
|
2005-11-04 |
2011-09-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
EP1951298A1
(de)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Grippeimpfstoffe mit adjuvantien und zytokin-induzierenden mitteln
|
EP2368572B1
(de)
|
2005-11-04 |
2020-03-04 |
Seqirus UK Limited |
Adjuvansimpfstoffe mit nicht virenähnlichen Antigenen aus Influenza-Viren, die in einer Zellkultur gezüchtet wurden
|
US7470674B2
(en)
*
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
US7776834B2
(en)
*
|
2005-11-07 |
2010-08-17 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
JP5215865B2
(ja)
|
2005-11-22 |
2013-06-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
ノロウイルス抗原およびサポウイルス抗原
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
JP2009520502A
(ja)
*
|
2005-12-20 |
2009-05-28 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Cgジヌクレオチド修飾物を含有するトール様受容体の新規な合成アゴニスト
|
NZ569168A
(en)
|
2005-12-22 |
2012-02-24 |
Glaxosmithkline Biolog Sa |
Streptococcus pneumoniae polysaccharide conjugate vaccine comprising 19F-DT conjugate
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
PT2478916T
(pt)
|
2006-01-27 |
2020-07-03 |
Seqirus Uk Ltd |
Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2382987A1
(de)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Lagerung von Influenza-Impfstoffen ohne Kühlung
|
SG170090A1
(en)
|
2006-03-30 |
2011-04-29 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
EP3456348A1
(de)
|
2006-09-11 |
2019-03-20 |
Seqirus UK Limited |
Herstellung von influenza-virus-impfstoffen ohne verwendung von eiern
|
PT2078080E
(pt)
|
2006-09-27 |
2015-09-18 |
Coley Pharm Gmbh |
Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
|
DE102006050655A1
(de)
*
|
2006-10-24 |
2008-04-30 |
Halmon Beheer B.V. |
Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
|
ES2480491T3
(es)
|
2006-12-06 |
2014-07-28 |
Novartis Ag |
Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
PT2148697E
(pt)
|
2007-05-24 |
2012-12-24 |
Glaxosmithkline Biolog Sa |
Composição liofilizada de wt-1 contendo cpg
|
KR101579947B1
(ko)
|
2007-06-26 |
2015-12-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
|
EP2484377A1
(de)
|
2007-06-27 |
2012-08-08 |
Novartis AG |
Influenza Impfstoffe mit wenig Zusatzstoffen
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
KR20100063048A
(ko)
*
|
2007-07-31 |
2010-06-10 |
더 존스 홉킨스 유니버시티 |
신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
AU2008299376B2
(en)
|
2007-09-12 |
2013-02-28 |
Glaxosmithkline Biologicals S.A. |
GAS57 mutant antigens and GAS57 antibodies
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
KR101773114B1
(ko)
|
2007-12-21 |
2017-08-30 |
노파르티스 아게 |
스트렙토라이신 o의 돌연변이 형태
|
EP3263591B1
(de)
|
2008-02-21 |
2019-03-27 |
GlaxoSmithKline Biologicals S.A. |
Meningokokken-fhbp-polypeptide
|
KR20100135766A
(ko)
|
2008-03-18 |
2010-12-27 |
노파르티스 아게 |
인플루엔자 바이러스 백신 항원 제조의 개선
|
EP2376633A1
(de)
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
EP2403526B1
(de)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia-antigene
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
SG176532A1
(en)
|
2009-06-15 |
2012-01-30 |
Univ Singapore |
Influenza vaccine, composition, and methods of use
|
AU2010269961A1
(en)
|
2009-07-07 |
2012-02-02 |
Novartis Ag |
Conserved Escherichia coli immunogens
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
EP2470204B1
(de)
|
2009-08-27 |
2015-12-16 |
GlaxoSmithKline Biologicals SA |
Hybridpolypeptide mit meningokokken-fhbp-sequenzen
|
CA2773637A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
AU2010302344A1
(en)
|
2009-09-30 |
2012-04-26 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
CA2779798C
(en)
|
2009-09-30 |
2019-03-19 |
Novartis Ag |
Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
MX2012004850A
(es)
|
2009-10-27 |
2012-05-22 |
Novartis Ag |
Polipeptidos fhbp meningococicos modificados.
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
JP2013529894A
(ja)
|
2010-04-07 |
2013-07-25 |
ノバルティス アーゲー |
パルボウイルスb19のウイルス様粒子を生成するための方法
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
KR20130108983A
(ko)
|
2010-05-26 |
2013-10-07 |
셀렉타 바이오사이언시즈, 인크. |
커플링되지 않은 애주번트를 갖는 나노담체 조성물
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
MX2013000163A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Metodos y composiciones inmunogenicas derivadas de norovirus.
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
WO2012061717A1
(en)
|
2010-11-05 |
2012-05-10 |
Selecta Biosciences, Inc. |
Modified nicotinic compounds and related methods
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
GB201021867D0
(en)
|
2010-12-23 |
2011-02-02 |
Mologen Ag |
Non-coding immunomodulatory DNA construct
|
CA2860331A1
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
EP4159232A1
(de)
|
2011-01-26 |
2023-04-05 |
GlaxoSmithKline Biologicals S.A. |
Rsv-immunisierungstherapie
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
EP3332802A1
(de)
|
2011-07-06 |
2018-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogene kombinationszusammensetzungen und ihre verwendung
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
US9149541B2
(en)
|
2011-07-08 |
2015-10-06 |
Novartis Ag |
Tyrosine ligation process
|
EP2736921B1
(de)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Zusammensetzungen und verfahren zum testen der funktionellen immunogenität von parvovirus-impfstoffen
|
CN103702687A
(zh)
|
2011-07-29 |
2014-04-02 |
西莱克塔生物科技公司 |
产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体
|
EP2755683B1
(de)
|
2011-09-14 |
2019-04-03 |
GlaxoSmithKline Biologicals SA |
Verfahren zur herstellung von saccharidprotein-glykokonjugaten
|
MX354924B
(es)
|
2011-11-07 |
2018-03-22 |
Novartis Ag |
Molecula portadora que comprende un antigeno spr0096 y un spr2021.
|
JP6073916B2
(ja)
|
2011-12-05 |
2017-02-01 |
ファクター バイオサイエンス インコーポレイテッド |
細胞に形質移入するための方法および製品
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
WO2013174832A1
(en)
|
2012-05-22 |
2013-11-28 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
MX363529B
(es)
|
2012-09-18 |
2019-03-27 |
Novartis Ag |
Vesículas de membrana externa.
|
MX2015004171A
(es)
|
2012-10-02 |
2015-10-22 |
Glaxosmithkline Biolog Sa |
Conjugados de sacaridos no lineales.
|
ES2848048T3
(es)
|
2012-10-03 |
2021-08-05 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas
|
BR122019025681B1
(pt)
|
2012-11-01 |
2023-04-18 |
Factor Bioscience Inc |
Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
|
ES2826555T3
(es)
|
2012-11-30 |
2021-05-18 |
Glaxosmithkline Biologicals Sa |
Antígenos de Pseudomonas y combinación de antígenos
|
CA2896537C
(en)
*
|
2013-01-08 |
2021-10-12 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
AU2014214844B2
(en)
|
2013-02-07 |
2017-12-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
WO2015117021A1
(en)
|
2014-01-31 |
2015-08-06 |
Factor Bioscience Inc. |
Methods and products for nucleic acid production and delivery
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
SI3122378T1
(sl)
|
2014-03-26 |
2020-03-31 |
Glaxosmithkline Biologicals S.A. |
Mutantni stafilokokni antigeni
|
KR102290205B1
(ko)
|
2014-06-04 |
2021-08-20 |
엑시큐어, 인크. |
예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달
|
WO2016081911A2
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
EP3229833A1
(de)
|
2014-12-10 |
2017-10-18 |
GlaxoSmithKline Biologicals SA |
Behandlungsverfahren
|
JP7199809B2
(ja)
|
2015-02-13 |
2023-01-06 |
ファクター バイオサイエンス インコーポレイテッド |
核酸製品及びその投与方法
|
US11013795B2
(en)
|
2015-06-26 |
2021-05-25 |
Seqirus UK Limited |
Antigenically matched influenza vaccines
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
CN109311265A
(zh)
|
2016-03-30 |
2019-02-05 |
3M创新有限公司 |
以随机分布的微球的预定图案为特征的制品及其制备方法
|
CA3033788A1
(en)
|
2016-08-17 |
2018-02-22 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
WO2018039629A2
(en)
|
2016-08-25 |
2018-03-01 |
Northwestern University |
Micellar spherical nucleic acids from thermoresponsive, traceless templates
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
US11167022B2
(en)
|
2017-03-31 |
2021-11-09 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
US11723966B2
(en)
|
2017-08-14 |
2023-08-15 |
Glaxosmithkline Biologicals Sa |
Methods of boosting immune responses
|
US20220000779A1
(en)
|
2018-12-06 |
2022-01-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
US20220221455A1
(en)
|
2019-04-18 |
2022-07-14 |
Glaxosmithkline Biologicals Sa |
Antigen binding proteins and assays
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
BR112021026565A2
(pt)
|
2019-08-05 |
2022-05-03 |
Glaxosmithkline Biologicals Sa |
Composição imunogênica
|
EP3799884A1
(de)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzungen
|
CN115175924A
(zh)
|
2020-02-26 |
2022-10-11 |
港大科桥有限公司 |
基于pd-1的针对冠状病毒感染的疫苗
|
JP2024510717A
(ja)
|
2021-02-22 |
2024-03-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物、使用及び方法
|
WO2023201109A1
(en)
|
2022-04-15 |
2023-10-19 |
Yale University |
Exatecan formulation
|